Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Company restores access to multiple sclerosis drug after pressure from neurologists.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Phase 3 Study of RPC1063 in Relapsing MS
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Treatment of acute transverse myelitis and its early complications.
Impact of MS during the critical window of brain development.
Extoxnet (extension toxicology network), 4-aminopyridine
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
4-aminopyridine toxicity: a case report and review of the literature.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Pages